We are live on
!
Find out more
SAM
Sectoral Asset Management Portfolio holdings
AUM
$121M
1-Year Est. Return
73.47%
This Fund
S&P 500
This Quarter
Est. Return
+7.82%
1 Year Est. Return
+73.47%
3 Year Est. Return
+165.77%
5 Year Est. Return
+169.27%
10 Year Est. Return
+1,136.49%
AUM
$968M
AUM Growth
-$1.1B
(-53%)
Cap. Flow
-$1.16B
Cap. Flow
% of AUM
-120.21%
Top 10 Holdings %
Top 10 Hldgs %
41.41%
Holding
89
New
8
Increased
13
Reduced
37
Closed
25
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$40.1M |
| 2 |
ABMD
Abiomed Inc
ABMD
|
+$24.4M |
| 3 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$19.9M |
| 4 |
ADPT
Adeptus Health Inc
ADPT
|
+$10.4M |
| 5 |
Teladoc Health
TDOC
|
+$5.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$112M |
| 2 |
Amgen
AMGN
|
+$102M |
| 3 |
Gilead Sciences
GILD
|
+$102M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$84.5M |
| 5 |
Regeneron Pharmaceuticals
REGN
|
+$83.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 94.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$17.2B
| $46M | 4.75% |
1,012,206
-637,757
| -39% | -$29.4M |
|
2
Merck
MRK
$315B
| $42.8M | 4.42% |
778,622
-7,288
| -0.9% | -$388K |
|
|
3
Pfizer
PFE
$143B
| $42M | 4.34% |
+1,256,716
| New | +$40.1M |
|
4
Eli Lilly
LLY
$1.05T
| $41.7M | 4.31% |
529,908
+23,213
| +5% | +$1.75M |
|
|
CELG
5
DELISTED
Celgene Corp
CELG
| $41.1M | 4.24% |
416,704
-1,082,034
| -72% | -$112M |
|
|
6
Gilead Sciences
GILD
$167B
| $39.7M | 4.1% |
476,102
-1,150,662
| -71% | -$102M |
|
|
NXTM
7
DELISTED
NxStage Medical Inc.
NXTM
| $39.6M | 4.09% |
1,828,582
+181,273
| +11% | +$3.23M |
|
|
8
BioMarin Pharmaceuticals
BMRN
$11.5B
| $38.5M | 3.98% |
494,836
-994,301
| -67% | -$84.5M |
|
9
Medtronic
MDT
$106B
| $36.9M | 3.81% |
425,333
-50,598
| -11% | -$4.09M |
|
|
ABMD
10
DELISTED
Abiomed Inc
ABMD
| $32.6M | 3.37% |
298,338
+244,738
| +457% | +$24.4M |
|
|
ADPT
11
DELISTED
Adeptus Health Inc
ADPT
| $32M | 3.3% |
619,108
+174,325
| +39% | +$10.4M |
|
12
DexCom
DXCM
$29.6B
| $31.3M | 3.23% |
1,577,864
-708,372
| -31% | -$12.1M |
|
13
Teva Pharmaceuticals
TEVA
$37.3B
| $30.9M | 3.19% |
615,935
+106,825
| +21% | +$5.69M |
|
|
ALXN
14
DELISTED
Alexion Pharmaceuticals
ALXN
| $29.3M | 3.03% |
251,348
-405,665
| -62% | -$57.6M |
|
|
PTLA
15
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $29M | 3% |
1,229,382
-363,657
| -23% | -$8.98M |
|
|
SHPG
16
DELISTED
Shire pic
SHPG
| $27.3M | 2.82% |
148,424
-256,923
| -63% | -$46.4M |
|
17
Acadia Healthcare
ACHC
$3.17B
| $26.6M | 2.75% |
480,605
+61,800
| +15% | +$3.61M |
|
|
FOLD
18
DELISTED
Amicus Therapeutics
FOLD
| $26.1M | 2.7% |
4,788,738
-4,437,407
| -48% | -$31M |
|
|
19
Teladoc Health
TDOC
$1.7B
| $23.5M | 2.42% |
1,464,221
+488,688
| +50% | +$5.7M |
|
20
UnitedHealth
UNH
$387B
| $20.5M | 2.12% |
145,095
-30,495
| -17% | -$4.07M |
|
21
Vertex Pharmaceuticals
VRTX
$123B
| $19.9M | 2.06% |
231,575
-664,904
| -74% | -$57.5M |
|
22
Incyte
INCY
$23.4B
| $19.9M | 2.05% |
248,459
-905,081
| -78% | -$70.3M |
|
23
Align Technology
ALGN
$12.7B
| $19.8M | 2.05% |
246,127
-176,359
| -42% | -$13.5M |
|
|
XLRN
24
DELISTED
Acceleron Pharma
XLRN
| $17.7M | 1.83% |
522,294
-914,941
| -64% | -$29.7M |
|
25
Viatris
VTRS
$20.1B
| $17.6M | 1.82% |
408,170
-181,457
| -31% | -$8.03M |
|
Similar funds
RIP
CCM
LFWA
FWA
CF
WIM
MW
AFC
Sectoral Asset Management's Q2 2016 Portfolio in Review
As of Q2 2016, Sectoral Asset Management held 89 positions worth $968M, down 53% from $2.07B the previous quarter. Its ten largest holdings account for 41% of the portfolio.
Sectoral Asset Management withdrew a net $1.16B in Q2 2016, closing 25 positions and reducing 37 holdings. Its most notable exit was Amgen, an estimated $102M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier.
Against the trend, Sectoral Asset Management opened a new position in Pfizer worth $42M.
- Sectoral Asset Management's largest Q2 2016 buy was Pfizer: 1,256,716 shares worth $42M.
- Sectoral Asset Management added most to Abiomed Inc in Q2 2016, an estimated $24.4M increase.
- Sectoral Asset Management's biggest Q2 2016 reduction was Celgene Corp, cutting an estimated $112M.
- Sectoral Asset Management fully exited Amgen in Q2 2016, selling an estimated $102M.
- Sectoral Asset Management's ten largest holdings make up 41% of its $968M portfolio in Q2 2016.
- Sectoral Asset Management opened 8 new positions and closed 25 in Q2 2016.
- Sectoral Asset Management's portfolio value fell 53% quarter-over-quarter to $968M.
Based on Sectoral Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.